Orteronel is primarily used in the treatment of prostate cancer, particularly in cases where the cancer has become resistant to traditional hormone therapies. It works by inhibiting the production of androgens, which are hormones that can promote the growth of prostate cancer cells. This makes it a valuable option for patients with metastatic castration-resistant prostate cancer (mCRPC), helping to slow disease progression and manage symptoms. Additionally, it is often used in combination with other treatments to enhance its effectiveness. Its targeted action on androgen synthesis offers a more focused approach to controlling the disease, improving the quality of life for patients.